Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of oncoprotein expressions in thyroid papillary carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the expressions of oncoproteins and to correlate the results with clinicopathologic parameters in papillary thyroid carcinoma (PTC). Papillary thyroid cancer (PTC) is the most common form and accounts for about 80% of all thyroid cancers. Although PTC generally has a good prognosis, some patients suffer from local recurrence and/or distant metastasis. Oncogenes have reported to be related not only in carcinogenesis but also in tumor prognosis, tumor type, differentiation and site of tumor in epithelial malignant tumors such as thyroid, breast, ovarian, and stomach cancer. This study was planned retrospectively and was performed in 87 patients (47 PTC, 40 benign lesions). The data of clinicopathologic parameters and tissue samples were collected from the archives. Sections stained with H&E were evaluated for each case and after confirming the diagnosis of PTC, oncoprotein expressions were determined by immunohistochemical analysis. The differences of oncoprotein expressions in PTC compared with control group were statistically significant. Cyclin D1 and p53 expressions were significantly increased in PTC. The expressions of bcl-2 and c-erbB-2 in PTC were found as increased, but the correlation between these proteins and poor prognostic parameters were not significant. We suggest that increased expressions of cyclin D1 and p53 could be used as prognostic factors in patients with PTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol. 2007;14:3403–11.

    Article  PubMed  Google Scholar 

  2. Duntas L, Grab-Duntas BM. Risk and prognostic factors f or differentiated thyroid cancer. Hell J Nucl Med. 2006;9:156–62.

    PubMed  Google Scholar 

  3. Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.

    PubMed  CAS  Google Scholar 

  4. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95.

    PubMed  CAS  Google Scholar 

  5. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1, 779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–8.

    PubMed  CAS  Google Scholar 

  6. Moore D, Ohene-Finko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology. 1998;32:35–42.

    Article  PubMed  CAS  Google Scholar 

  7. Utrilla JC, Martin-Lacave I, San Martin MV, Fernandez-Santos JM, Galera-Davidson H. Expression of c-erbB-2 oncoprotein in human thyroid tumours. Histopathology. 1999;34:60–5.

    Article  PubMed  CAS  Google Scholar 

  8. Muro-Cacho CA, Holt T, Klotch D, Mora L, Livingston S, Futran N. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg. 1999;120:200–7.

    Article  PubMed  CAS  Google Scholar 

  9. Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med. 1985;313:428–36.

    Article  PubMed  CAS  Google Scholar 

  10. Tantawy A, Youins L, Hamza M. Expression of c-erbB-2 oncoprotein in cancer of the larynx in relation to invasion of the cartilagenous framework and prognosis. Eur Arch Otorhinolaryngol. 1999;256:72–7.

    Article  PubMed  CAS  Google Scholar 

  11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.

    Article  PubMed  CAS  Google Scholar 

  12. Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer. 1998;76:806–11.

    Article  PubMed  CAS  Google Scholar 

  13. Zou M, Shi Y, Farid NR, al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine. 1998;8:61–4.

    Article  PubMed  CAS  Google Scholar 

  14. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med. 1987;316:79–84.

    Article  PubMed  CAS  Google Scholar 

  15. Lal G, Clark OH. Thyroid, parathyroid and adrenal. In: Schwartz SI, editor. Principles of surgery. New York: F.C.Brunicardi-Hill Book Comp; 2005. p. 1395–470.

    Google Scholar 

  16. Pilloti S, Collini P, Rike F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol. 1994;172:337–42.

    Article  Google Scholar 

  17. Morita N, Ikeda Y, Takami H. Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg. 2008;32:2617–22.

    Article  PubMed  Google Scholar 

  18. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95.

    PubMed  CAS  Google Scholar 

  19. Horie S, Maeta H, Endo K, Ueta T, Takashima K, Terada T. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: correlations with clinicopathologic features. Pathol Int. 2001;51:11–5.

    Article  PubMed  CAS  Google Scholar 

  20. Temmim L, Ebraheem AK, Baker H, Sinowatz F. Cyclin D1 protein expression in human thyroid gland and thyroid cancer. Anat Histol Embryol. 2006;35:125–9.

    Article  PubMed  CAS  Google Scholar 

  21. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol. 2000;13:882–7.

    Article  PubMed  CAS  Google Scholar 

  22. Lantsov D, Meirmanov S, Nakashima M, Kondo H, Saenko V, Naruke Y, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology. 2005;47:248–56.

    Article  PubMed  CAS  Google Scholar 

  23. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:1814–8.

    Article  PubMed  CAS  Google Scholar 

  24. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26(4 Suppl 12):51–9.

    PubMed  CAS  Google Scholar 

  25. Carroway KL 3rd, Sweeney C. Localization and modulation of ErbB receptor tyrosine kinases. Curr Opin Cell Biol. 2001;13:1225–30.

    Google Scholar 

  26. Nagy P, Jenei A, Damjanovich S, Jovin TM, Szölosi J. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. Pathol Oncol Res. 1999;5:255–71.

    Article  PubMed  CAS  Google Scholar 

  27. Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322–8.

    PubMed  CAS  Google Scholar 

  28. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–205.

    PubMed  CAS  Google Scholar 

  29. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, et al. Differential expression of the c-erbB-2gene in human small cell and non-small cell lung cancer. Cancer Res. 1989;49:4968–71.

    PubMed  CAS  Google Scholar 

  30. Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57:285–90.

    Article  PubMed  CAS  Google Scholar 

  31. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998;55:475–81.

    Article  PubMed  CAS  Google Scholar 

  32. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556–67.

    PubMed  CAS  Google Scholar 

  33. Freudenberg LS, Sheu S, Görges R, Mann K, Bokler S, Frilling A, et al. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma. Nuklearmedizin. 2005;44:179–84.

    PubMed  CAS  Google Scholar 

  34. Mondi MM, Rich R, Ituarte P, Wong M, Bergman S, Clark OH, et al. HER2 expression in thyroid tumors. Am Surg. 2003;69:1100–3.

    PubMed  Google Scholar 

  35. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c- myc and bcl-2 proto-oncogenes. Nature. 1992;359:554–6.

    Article  PubMed  CAS  Google Scholar 

  36. Mitselou A, Peschos D, Dallas P, Charalabopoulos K, Agnantis NJ, Vougiouklakis T. Immunohistochemical analysis of bcl-2 protein in papillary thyroid carcinomas and papillary microcarcinomas of the thyroid gland. Exp oncol. 2004;26:282–6.

    PubMed  Google Scholar 

  37. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down- regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19.

    Article  PubMed  CAS  Google Scholar 

  38. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chir Belg. 2005;105:644–8.

    PubMed  CAS  Google Scholar 

  39. Mitselou A, Loachim E, Kitsou E, Vougiouklakis Th, Zagorianakou N, Makrydimas G, et al. Immunohistochemical study of apoptosis-related bcl-2 protein and its correlation with proliferation indices (Ki-67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. In vivo. 2003;17:469–77.

    PubMed  CAS  Google Scholar 

  40. Loachim E, Kitsiou E, Mitselou A, Zagorianakou N, Charalabopoulos K, Salmas M, et al. P21 (waf/cip 1) protein expression in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status, c-erbB-2 oncoprotein, bcl-2 and other cell cycle related proteins (pb, p53, ki-67, PCNA). Exp Oncol. 2003;25:200–5.

    Google Scholar 

  41. Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R, et al. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patient. Tumour Biol. 2005;26:57–64.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Gulhane Military Medical Academy, Haydarpasa Training Hospital, Istanbul, Turkey

    A. Z. Balta, A. I. Filiz, Y. Kurt, I. Sucullu, E. Yucel & M. L. Akin

  2. Department of Surgery, GATA Haydarpasa Teaching Hospital, Selimiye Mah. Tibbiye Cad., 34668, Kadıköy, Istanbul, Turkey

    A. Z. Balta

Authors
  1. A. Z. Balta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. I. Filiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Sucullu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Yucel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. L. Akin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Z. Balta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balta, A.Z., Filiz, A.I., Kurt, Y. et al. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol 29, 734–741 (2012). https://doi.org/10.1007/s12032-011-9969-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9969-x

Keywords

Search

Navigation